Illumina sees 2025 EPS of $4.50 after China ban, consensus $4.51

Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing instruments into China. Illumina said it “respects MOFCOM’s decision and will continue to comply with all applicable laws and regulations wherever the company operates.” Illumina said it will continue expanding its multiomics portfolio “with new roadmap technologies spanning genomics, spatial, single cell, and methylation, as well as a new multimodal data analysis platform.” Illumina also announced it expects fiscal 2025 non-GAAP diluted earnings per share of approximately $4.50. The consensus estimate is $4.51. The company added, “Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today. We will continue to invest in our growth strategy, while taking actions to achieve EPS of approximately $4.50 in 2025, and then grow from there.”